Endometrial cancer is the most common malignancy of the female genital tract in the world and the seventh most common cause of death from cancer in women in western Europe. Every year 7406 new cases are registered in the UK, 88 068 in the European Union and 40 102 in North America.
diagnosis
Most cases of endometrial cancer are diagnosed in early stages because of abnormal uterine bleeding as the presenting symptom in 90% of the cases.
The best diagnostic strategy in patients with postmenopausal bleeding still remains controversial. In the past, the principal method of investigation was dilatation and curettage (D&C). Now endometrial biopsy and hysteroscopy have almost completely replaced D&C. The Pipelle or the Vabra devices used for endometrial sampling are very sensitive techniques for the detection of endometrial carcinoma (99.6 and 97.1%). A recent study concludes that the first step in the diagnostic pathway should be the measurement of endometrial thickness, using a cut-off point of 3 or 4 mm, followed by endometrial sampling. Saline infusion sonography can be used to distinguish between focal and diffuse pathology. Hysteroscopy should be used as the final step in the diagnostic pathway of women with postmenopausal bleeding.
histopathological characteristics
Two main types of endometrial carcinoma have been recognized on the basis of clinical, pathological and molecular features. Type I or endometrioid adenocarcinomas represent 80% of endometrial carcinomas and serous carcinomas are the prototype of type II carcinomas. Endometrial carcinomas, at least in well-differentiated form, are composed of glands that resemble those of the normal endometrium and can be associated with or preceded by endometrial hyperplasia. In the most widely accepted grading systems, the rate of solid to glandular component (<5% for grade 1 and >50% for grade 3) defines three architectural grades. Serous carcinomas are all high-grade carcinomas. They have several features in common with serous carcinomas of the ovary and Fallopian tube, including the association with a form of intraepithelial serous carcinoma, referred to as 'endometrial intraepithelial carcinoma' (EIC), a lesion which is thought to be the precursor lesion. Clear cell carcinomas are rare, comprising 1% of endometrial adenocarcinomas. Endometrioid adenocarcinomas frequently show microsatellite instability and mutations of the PTEN, PIK3CA, K-Ras and b-catenin genes. Microsatellite instability is typically found in patients with hereditary nonpolyposis colon cancer. The b-catenin gene is more frequently mutated in carcinomas with squamous differentiation. Serous carcinomas are characterized by p53 mutations and chromosomal instability. Clear cell carcinomas have absent reactivity for estrogen and progesterone receptors and low immunoreactivity for p53.
staging and risk assessment
Endometrial cancer is generally staged according to the International Federation of Gynecology and Obstetrics (FIGO) system. Since 1988, the FIGO system has recommended surgical staging with systematic pelvic and para-aortic lymphadenectomy. In May 2009, a new FIGO staging system was published, but the existing literature and evidence are based on the old classification (Tables 1 and 2 The role of systematic pelvic lymphadenectomy is an issue of current debate. In an Italian study, 514 patients with stage I endometrial cancer were randomized (excluding stage IA-IB G1 and non-endometrioid histotype). In this study, systematic lymphadenectomy did not improve disease-free or overall survival. In the ASTEC trial, women with malignancies confined to the uterus were randomized. In this trial there was no evidence of benefit on overall survival or recurrence-free survival when pelvic lymphadenectomy was performed. The authors concluded that routine systematic pelvic lymphadenectomy cannot be recommended in women with stage I endometrial cancer, unless enrolled in clinical trials.
Lymphadenectomy is highly important in determining a patient's prognosis and in tailoring adjuvant therapies. adjuvant treatment (Table 4) radiotherapy
to show any difference in overall survival or progression-free survival (PFS). The quality of life was better in the vaginal brachytherapy arm. 
locoregional recurrence
The standard treatment for vaginal recurrence is radiation therapy (external beam plus vaginal brachytherapy): with high rates of local control, complete response (CR) and 5-year survival is 50%. For central pelvic recurrence the treatment of choice is surgery or radiation therapy, while for regional pelvic recurrences it is radiation therapy, associated if possible with chemotherapy.
advanced disease
There is no agreement on the standard treatment for women with advanced endometrial cancer. Typically, a combination of surgery, radiotherapy and/or chemotherapy is employed.
In the GOG-122 trial, there were 396 patients with stage III and optimally debulked stage IV disease who were randomized to whole abdominal radiation or to doxorubicin-cisplatin chemotherapy; there was a significant improvement in both PFS (50% vs.38%; P = 0.07) and overall survival (55% vs.42%; P = 0.004) in favor of chemotherapy.
treatment of metastatic disease and relapse
Systemic treatment for metastatic and relapsed disease may consist of endocrine therapy or cytotoxic chemotherapy. Hormonal therapy is recommended for endometrioid histologies only and involves mainly the use of progestational agents; tamoxifen and aromatase inhibitors are also being used. The main predictors of response in the treatment of metastatic disease are well-differentiated tumors, a long disease-free interval and the location and extent of extrapelvic (particularly pulmonary) metastases. The overall response to progestins is 25%. Single cytotoxic agents have been reported to achieve a response rate up to 40% in chemotherapy-naïve patients with metastatic endometrial cancer. Among those, platinum compounds, anthracyclines and taxanes are most commonly used alone and in combination.
In non-randomized trials, paclitaxel with carboplatin or cisplatin demonstrated a response rate >60% and a possibly prolonged survival compared with historical experience with other non paclitaxel-containing regimens. Based upon these results, many consider that paclitaxel-based combination regimens are preferred for first-line chemotherapy of advanced and recurrent endometrial cancer. Endometrial cancer recurring after first-line chemotherapy is largely a chemoresistant disease. Various agents have been tested in a number of small phase II trials in patients previously exposed to chemotherapy. Only paclitaxel has consistently shown a response rate >20%. In a recently published study, the combination of weekly topotecan and docetaxel had clinical benefit and was well tolerated in heavily pretreated patients.
papillary serous carcinoma and clear cell carcinoma
Papillary serous and clear cell carcinoma require complete staging with total hysterectomy, bilateral salpingooophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy, appendicectomy and peritoneal biopsies. They are more aggressive with higher rates of metastatic disease and lower 5-year survival rates [I, A].
There is considerable evidence from retrospective series that platinum-based adjuvant chemotherapy for early (stage I and II) disease improves PFS and overall survival [III, B]. Platinumbased chemotherapy is recommended in patients with stage III or IV [I, A]. The same chemotherapy regimens usually employed for epithelial ovarian cancer can be considered in women with advanced or recurrent papillary serous or clear cell uterine cancer. Historically papillary serous endometrial carcinomas have not be considered to be hormone responsive.
prognosis
In the USA, the overall 5-year survival rate in women with endometrial cancer is 83%.
A key factor leading to this high rate is that most cases are diagnosed at an early stage.
The Two recent studies conclude that the revised FIGO 2009 system is highly prognostic. The reduction in stage I substages, the elimination of cervical glandular involvement and the stratification of women with nodal disease all improved the performance of the staging system. On the contrary, another study suggests that the 2009 FIGO system does not improve predictive ability over the 1988 system.
Regarding the new staging system, future research should be focused on developing individualized risk models in endometrial cancer.
follow-up
Most recurrences will occur within the first 3 years after treatment. Patients should undergo follow-up every 3-4 months with physical and gynecological examination for the first 2 years, and then with a 6 month interval until 5 years. 
